PMC4243802_01
Computed tomography imaging of a 48-year-old patient with metastatic breast cancer at progression following first-line treatment with six cycles of conventional paclitaxel 90 mg/m2 QW 3/4 plus bevacizumab 10 mg/kg Q2W for 12 months (a) and then after the first three cycles of second-line treatment with nab-paclitaxel 260 mg/m2 Q3W (b). Arrows show the extent of the left chest wall lesion before and after nab-paclitaxel therapy. Q2W, every 2 weeks; Q3W, every 3 weeks; QW 3/4, weekly for 3 weeks of a 4 week cycle.
cad-26-117-g002.jpg
PMC4243802_01_cad-26-117-g002.jpg
F1
April 2011, when an increase in the left chest wall lesion dimensions was detected along with a single infraclavicular lymph node metastasis (Fig. 1a). As the patient had received six cycles of epirubicin as part of her adjuvant therapy and developed relapse after 9 months, she was considered anthracycline resistant. After three cycles, the left chest wall lesion and the infraclavicular lymph node metastasis were undetectable (Fig. 1b), and the patient was considered to have achieved a complete response according to Response Evaluation Criteria for Solid Tumors.